<DOC>
	<DOCNO>NCT01071798</DOCNO>
	<brief_summary>This prospective observational study aim evaluate safety , application onset effect rituximab clinical routine treatment severe active rheumatoid arthritis first 6 month ( case re-therapy : 12 month ) .</brief_summary>
	<brief_title>An Observational Study Safety Effectiveness Rituximab Patients With Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>No pretreatment rituximab Age 18 year old Patients active , severe rheumatoid arthritis prescription rituximab accord German Summary Product Characteristics ( SmPC `` Fachinformation '' ) Patients sign informed consent Female patient secure contraception Violation Selection criterion : 1 . Active severe infection 2 . Severe heart failure ( NYHA class IV ) severe , uncontrollable heart disease 3 . Participation interventional study within last 3 month therapy start rituximab 4 . Pretreatment rituximab 5 . Age &lt; 18 year 6 . Known intolerability monoclonal antibody chimeric monoclonal antibody 7 . Known pregnancy breastfeed Data patient without approval data physician Patients without informed consent Double documentation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>